Noopur Suresh Raje MD

PubMed

• Multiple myeloma: What is the most cost-effective imaging strategy for initial detection of bone lesions?
  Soterios Gyftopoulos, Arnau Hanly, Naveen Subhas, Noopur Raje, Connie Y Chang
  Skeletal Radiology. 2025-05-01
• Remineralization Rate of Lytic Lesions of the Spine in Multiple Myeloma Patients Undergoing Radiation Therapy.
  Hester Zijlstra, Jens P Te Velde, Brendan M Striano, Olivier Q Groot, Tom M de Groot
  Global Spine Journal. 2025-04-01
• Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment.
  Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, Mark B Leick, Md Raihan Chowdhury
  Blood. 2025-03-31

Journal Articles

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma  
  Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine
• Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
  Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
• Role of the RANK/RANKL Pathway in Multiple Myeloma  
  Noopur Raje, MD, Clinical Cancer Research
• A Phase 1/2 Study of Evofosfamide, A Hypoxia-Activated Prodrug with or Without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma  
  Noopur S Raje, Ira Zackon, Clinical Cancer Research
• Join now to see all

Abstracts/Posters

• Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteri...
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma
  Noopur Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
  Noopur Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
  Noopur S. Raje, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Hematologic Malignancies—Plasma Cell Dyscrasia 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Analysis of Hospitalization and Readmissions after CAR T Cell Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind,... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenstrom Macroglobulinemia, and Amyloidosis 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Managing Multiple Myeloma: What's Next? 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all